Ligand Pharma (LGND) Tops Q4 EPS by 63c, Offers Guidance

Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.62, $0.63 better than the analyst estimate of $0.99. Revenue for the quarter came in at $70 million versus the consensus estimate of $54.24 million.

GUIDANCE:

Ligand Pharma sees FY2021 EPS of $6.00, versus the consensus of $6.09. Ligand Pharma sees FY2021 revenue of $291 million, versus the consensus of $289 million.

• Ligand is raising its 2021 financial guidance. Ligand now expects total revenues to be approximately $291 million and adjusted diluted EPS to be approximately $6.15, up from previous guidance for total revenues of approximately $285 million and adjusted diluted EPS of approximately $6.00. This updated guidance reflects yesterday’s announcement by Travere Therapeutics of positive pivotal Phase 3 data and potential NDA filing in 2021 for sparsentan, with a milestone payment due to Ligand upon NDA submission.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
• BioNTech and Bristol Myers Squibb report Phase 2 data for pumitamig in NSCLC
• Meta's capital-raising plans expose a major weakness in the AI boom